About AEON BioPharma
AEON BioPharma is a company based in Newport Beach (United States) founded in 2018.. AEON BioPharma has raised $30 million across 2 funding rounds from investors including Daewoong Pharmaceutical. The company has 5 employees as of December 31, 2024. AEON BioPharma offers products and services including ABP-450. AEON BioPharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Newport Beach, United States
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aeon Biopharma, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$42.01 M110.92as on Dec 31, 2024
-
EBITDA
$-27.73 M47.42as on Dec 31, 2024
-
Total Equity Funding
$30 M (USD)
in 2 rounds
-
Latest Funding Round
$54.5 M (USD), Post-IPO
Aug 10, 2022
- Investors
-
Employee Count
5
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AEON BioPharma
AEON BioPharma is a publicly listed company on the AMEX with ticker symbol AEON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AEON BioPharma
AEON BioPharma offers a comprehensive portfolio of products and services, including ABP-450. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Neurotoxin treatment for nerve and muscle-based disorders
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of AEON BioPharma
AEON BioPharma has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54.5 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $54.5M
-
First Round
First Round
(03 Sep 2020)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Post-IPO - AEON BioPharma | Valuation |
investors |
|
| Sep, 2020 | Amount | Series B - AEON BioPharma | Valuation | Daewoong Pharmaceutical |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AEON BioPharma
AEON BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for gastrointestinal disorders and related diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AEON BioPharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AEON BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aeon Biopharma Comparisons
Competitors of AEON BioPharma
AEON BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aeon Biopharma
Frequently Asked Questions about AEON BioPharma
When was AEON BioPharma founded?
AEON BioPharma was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is AEON BioPharma located?
AEON BioPharma is headquartered in Newport Beach, United States. It is registered at Newport Beach, California, United States.
Who is the current CEO of AEON BioPharma?
Marc Forth is the current CEO of AEON BioPharma.
Is AEON BioPharma a funded company?
AEON BioPharma is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Sep 03, 2020.
How many employees does AEON BioPharma have?
As of Dec 31, 2024, the latest employee count at AEON BioPharma is 5.
What does AEON BioPharma do?
AEON BioPharma was founded in 2018 and is headquartered in Newport Beach, United States. Bio-therapeutics targeted at nervous system-related conditions are developed by the company within the biopharmaceutical sector. Operations focus on innovative treatments, including the flagship product ABP-450, a 900 kDa prabotulinumtoxinA formulation. This product is utilized for managing disabling disorders in patients, with ongoing efforts centered on clinical advancement and therapeutic delivery.
Who are the top competitors of AEON BioPharma?
AEON BioPharma's top competitors include Jazz Pharmaceuticals, Flexion Therapeutics and PTC Therapeutics.
What products or services does AEON BioPharma offer?
AEON BioPharma offers ABP-450.
Is AEON BioPharma publicly traded?
Yes, AEON BioPharma is publicly traded on AMEX under the ticker symbol AEON.
Who are AEON BioPharma's investors?
AEON BioPharma has 1 investor. Key investors include Daewoong Pharmaceutical.
What is AEON BioPharma's ticker symbol?
The ticker symbol of AEON BioPharma is AEON on AMEX.